The research, led by Chenjing Zhang and colleagues at Fujian Agriculture and Forestry University, focused on 20-hydroxyecdysone, or 20E, the major bioactive ecdysteroid produced by A. bidentata. Ecdysteroids are best known as the molting hormones of insects, but plants in the Amaranthaceae family synthesize them in remarkable quantities, and their ecological roles have remained only partially understood. What made 20E a compelling suspect in the continuous-cropping mystery was its documented capacity to influence microbial growth: it can stimulate beneficial bacteria and, intriguingly, affect the potentially pathogenic fungus Fusarium oxysporum, a soil dweller responsible for devastating wilt diseases in countless crops worldwide. The team hypothesized that the plant’s ability to thrive under repeated cultivation might hinge on how much 20E it pumps into its root zone.

To trace the pathway from gene to ecosystem, the investigators combined three complementary approaches: field association analysis across plots with different durations of continuous cropping, functional manipulation of a candidate biosynthetic gene, and controlled experiments with purified 20E and root exudates. The field surveys delivered the first crucial pattern. As continuous cropping stretched over multiple years, 20E accumulation in the plant rose in tandem with increasing abundances of two bacterial genera, Bacillus and Pseudomonas, both widely recognized as plant-beneficial groups capable of suppressing disease and promoting growth. Strikingly, Fusarium oxysporum showed no sustained accumulation in these long-term plots, defying the expectation that a pathogenic fungus would flourish as monoculture continues.

Correlation analysis sharpened this picture considerably. Traits related to 20E were positively associated with the abundances of the beneficial bacteria and negatively associated with F. oxysporum. In other words, the more 20E the system contained, the more the rhizosphere tilted toward a protective microbial assembly and away from a disease-prone one. This statistical signature suggested, but did not prove, a causal chain running from the plant’s sterol metabolism through 20E production to the composition of its microbial entourage. Establishing that chain required identifying and manipulating the enzyme at the top of the pathway.

That enzyme is sterol Δ7-reductase, known as DHCR7, a key player in sterol biosynthesis that shapes the sterol composition of cells. Because sterols provide the precursor backbone from which ecdysteroids like 20E are built, DHCR7 sits at a critical regulatory junction. The team identified, for the first time in A. bidentata, two paralogous copies of the gene, which they named AbDHCR7-1 and AbDHCR7-2. Both copies were significantly induced by long-term continuous cropping, hinting that the plant ramps up its sterol-processing machinery precisely when the soil environment becomes most challenging, a response consistent with metabolic adaptation rather than decline.

The functional experiments then delivered the study’s most dramatic numbers. When the researchers overexpressed AbDHCR7-1 in hairy root cultures, 20E contents surged by 222 percent compared with controls; overexpression of AbDHCR7-2 produced a 111 percent increase. The root exudates, the chemical cocktail that roots release into the surrounding soil, also showed a tendency toward higher 20E levels in the overexpression lines, meaning the hormone was not merely accumulating inside the tissue but was being exported into the rhizosphere where microbes would encounter it. Conversely, when the team used virus-induced gene silencing to knock down AbDHCR7 expression, 20E accumulation dropped. The dose-response relationship between the gene and the metabolite was now firmly established in both directions.

The decisive test came in soil. In a controlled pot experiment using substrate taken from the one-year continuous-cropping field treatment, the researchers applied hairy-root exudates harvested from the overexpression lines. The result was a measurable shift in the soil community: rhizosphere abundances of Bacillus and Pseudomonas increased significantly, while the abundance of F. oxysporum decreased. This experiment connected the molecular manipulation directly to ecological outcomes, demonstrating that a plant’s engineered metabolic output, delivered through its natural exudation channels, could restructure the microbial neighborhood in a direction favorable to the plant. It is the kind of host-driven microbiome management that microbiologists have theorized about but rarely documented with such a complete chain of evidence.

Complementary assays filled in the mechanistic details of how individual microbes respond to 20E itself. Exogenous 20E treatment and in vitro culture experiments showed differential responses among the targeted organisms: the beneficial bacteria responded positively to the compound, growing and enriching in its presence, whereas F. oxysporum exhibited an inhibitory response. This selectivity is what makes the system so elegant from the plant’s perspective. A single exported metabolite acts simultaneously as a lure for allies and a deterrent for an enemy, achieving through chemistry what many crops cannot achieve even with intensive agricultural intervention. The differential sensitivity also suggests that the microbial community structure under long-term cropping is not a random byproduct of soil fatigue but an actively sculpted outcome of host metabolism.

The broader implications of the work extend in two directions. For the study of medicinal plants, it provides the first functional link between a DHCR7 enzyme and 20E accumulation in A. bidentata, opening the possibility of breeding or engineering varieties with optimized ecdysteroid profiles, both for pharmacological yield and for soil resilience. For agriculture at large, it offers a template for rhizosphere microbiome management based on host-specific metabolites rather than external inputs such as pesticides or microbial inoculants. If crops could be tuned to exude the right compounds at the right times, the soil itself might be enlisted as a partner in disease suppression. The authors note that their findings provide a basis for further understanding the mechanisms underlying continuous-cropping adaptation in medicinal plants, and the field system they describe, spanning multiple years of repeated cultivation, offers a rare natural experiment in how a plant and its microbial partners co-evolve under sustained monoculture pressure.

There is also a conceptual lesson in the study’s reversal of expectations. Continuous cropping is conventionally framed as a story of degradation: nutrients deplete, pathogens accumulate, and microbial diversity collapses. A. bidentata demonstrates that the trajectory can run differently when the host possesses the right metabolic machinery. By upregulating sterol metabolism under stress, the plant converts an increasingly hostile soil environment into an increasingly selective one, filtering its microbial associates through the lens of 20E. Whether similar mechanisms operate in other ecdysteroid-producing species, or whether the principle can be transferred to crops that lack such chemistry, remains an open question. But the demonstration that a single biosynthetic gene can ripple outward from sterol composition to hormone export to bacterial enrichment and fungal suppression marks a significant step toward understanding plants not as passive victims of their soil, but as active architects of the living world that surrounds their roots.

Subject of Research: Regulation of 20-hydroxyecdysone biosynthesis by AbDHCR7 and its effects on rhizosphere microbial communities in Achyranthes bidentata under continuous cropping

Article Title: AbDHCR7 regulates 20-hydroxyecdysone accumulation in Achyranthes bidentata and contributes to differential responses of targeted rhizosphere microorganisms

Article References: Zhang, C., Zhang, B., Zhang, S., Chen, Y., Zhang, M., Li, J., Zeng, C., Fang, Z., Zhong, S., Jiao, Y., Xu, H., Qin, B., Chen, T., Lin, S., Liu, Y., Fang, C., & Lin, W. (2026). AbDHCR7 regulates 20-hydroxyecdysone accumulation in Achyranthes bidentata and contributes to differential responses of targeted rhizosphere microorganisms. BMC Plant Biology. https://doi.org/10.1186/s12870-026-10100-z

Image Credits: AI Generated

DOI: 10.1186/s12870-026-10100-z

Keywords: Achyranthes bidentata, AbDHCR7, 20-hydroxyecdysone, rhizosphere microbiome, continuous cropping, root exudates, Bacillus, Pseudomonas, Fusarium oxysporum, sterol biosynthesis, medicinal plants, plant-microbe interactions

The scale of the problem justifies the ambition. Current treatments for leishmaniasis, including pentavalent antimonials, amphotericin B, miltefosine, paromomycin and sitamaquine, are constrained by toxicity, high cost, long treatment courses, treatment failure and the steady emergence of drug-resistant parasites. These shortcomings are particularly damaging for visceral leishmaniasis, the most dangerous form of the disease, and for cutaneous and mucosal manifestations that leave lasting scars and stigma. Because no licensed human vaccine exists, chemotherapy remains the principal line of defence, which makes the erosion of drug efficacy a direct threat to public health in endemic countries.

Compounding the therapeutic challenge is the peculiar biology of Leishmania itself. The parasites display remarkable genomic plasticity, characterised by mosaic aneuploidy, in which individual chromosomes exist in variable copy numbers within the same population, alongside widespread copy number variation. This fluid genome architecture allows rapid adaptation under drug pressure and complicates the identification of durable molecular targets, since a gene that appears essential in one strain or life stage may be buffered by extra copies in another. The review emphasises that any credible target-discovery effort must therefore account for this adaptive capacity, favouring approaches that validate essentiality and resistance liability experimentally rather than relying on static genome annotations alone.

Multi-omics technologies form the first pillar of the proposed framework. Comparative genomics across Leishmania species, transcriptome diversity mapped by nanopore direct RNA sequencing, proteomic surveys of organelles such as glycosomes, lipidomic analyses of extracellular vesicles from resistant parasites, and single-cell transcriptomics of infected macrophages together reveal the pathways that sustain parasite survival, virulence and drug tolerance. Recent single-cell studies have exposed rare parasitised cell populations in chronic Leishmania donovani infection and lipid metabolism reprogramming in macrophages during early infection, while spatial mapping of cutaneous lesions has uncovered distinct tissue-level immune programmes. These datasets collectively illuminate host–parasite interplay at unprecedented resolution and nominate candidate vulnerabilities for therapeutic intervention.

The second pillar is CRISPR-based genome engineering, which has matured from the first Cas9 edits in Leishmania in 2015 into a versatile toolbox for functional genomics. High-throughput CRISPR-Cas9 screens in Leishmania infantum have been used to dissect drug resistance, cytosine base editor toolboxes such as LeishBASEedit enable scalable loss-of-function studies, and CRISPR-Cas13b knockdowns extend editing to RNA-level perturbations. Systematic deletion screens, including the TransLeish effort that identified membrane transporters essential for intracellular survival, and resources such as LeishGEM, which catalogues genome-wide deletion mutant fitness and protein localisation, now allow researchers to confirm which candidate targets are genuinely indispensable. The review highlights how these tools also expose resistance mechanisms, from single amino acid substitutions conferring antimony tolerance to genes required for susceptibility to miltefosine.

Artificial intelligence constitutes the third pillar, converting the growing data flood into prioritised hypotheses. Machine-learning models trained on molecular fingerprints can predict leishmanial activity, ensemble techniques improve those predictions, and deep multitask learning has already guided the discovery of new compounds active against L. infantum. Graph-embedding approaches have uncovered potent candidate molecules, while AI-empowered platforms such as cidalsDB aggregate anti-pathogen therapeutics research. The authors describe how AI-assisted predictive modelling supports target prioritisation, virtual screening and structure-guided drug design, and they situate these methods within the broader rise of foundation models and digital twins in drug discovery, technologies that promise to compress timelines and reduce attrition when coupled with rigorous validation and uncertainty quantification.

From this convergence, the review identifies several high-priority therapeutic pathways. Redox homeostasis stands out because Leishmania relies on the trypanothione system, comprising trypanothione reductase and trypanothione synthetase, rather than the glutathione chemistry of its mammalian hosts, offering a selectivity window that inhibitor programmes are actively exploiting. Sterol biosynthesis provides another validated axis: the cytochrome P450 sterol 14-alpha-demethylase CYP51, its reductase partner P450R1, sterol C4-methyl oxidase and sterol C24-methyltransferase all influence membrane integrity and drug sensitivity. MAP kinase signalling, mitochondrial electron transport at the quinone reduction site of cytochrome b, and arginine metabolism round out the target landscape, each supported by genetic or pharmacological evidence of importance to parasite viability or infectivity.

The fourth pillar shifts the therapeutic lens from the parasite to the host. Host-directed immunotherapy seeks to reinvigorate the macrophage and T-cell responses that control infection, for example by promoting interferon-gamma signalling, inducible nitric oxide synthase activity and nitric oxide production through pathways involving Toll-like receptors, the JAK–STAT axis and mTOR regulation. Because such approaches do not exert direct pressure on parasite genes, they are inherently less likely to select for resistance and can complement parasite-directed drugs, potentially shortening regimens and improving outcomes in immunocompromised patients. The review surveys candidate host-directed agents and argues that combining them with precision antileishmanials represents a strategically sound route to resistance-resilient therapy.

The authors are candid about the obstacles ahead. Leishmania’s unusual gene expression regime, in which genes are transcribed in long polycistronic clusters and controlled largely post-transcriptionally, complicates both functional screens and AI models trained on conventional eukaryotic assumptions. Genetic diversity across species and within emerging transmission foci means that targets validated in one parasite may not translate to another, and data quality, model interpretability and experimental validation remain bottlenecks for computational discovery. Delivering host-directed therapies safely also demands careful immunological profiling to avoid exacerbating pathology in tissues where an overexuberant inflammatory response drives disease.

Nevertheless, the review’s central message is one of cautious optimism: the pieces of a precision drug-discovery pipeline for leishmaniasis now exist and can be connected. Omics surveys nominate pathways, CRISPR screens validate essentiality and map resistance, AI prioritises targets and designs molecules against them, and host-directed immunotherapy adds a complementary, resistance-sparing modality. If the research community and funders invest in integrating these strands, the authors conclude, the field can move beyond the incremental repurposing that has dominated recent decades and toward safer, more efficient and durable treatments for one of the world’s most neglected tropical diseases.

Subject of Research: Precision drug discovery for leishmaniasis using multi-omics, CRISPR functional genomics, artificial intelligence and host-directed therapeutics

Article Title: Towards precision antileishmanial drug discovery: Integrating multi-omics, functional genomics, artificial intelligence and host-directed therapeutics

Article References: TOPUZ ATA, D., ATA, A., & ODACI, Z. T. (2026). Towards precision antileishmanial drug discovery: Integrating multi-omics, functional genomics, artificial intelligence and host-directed therapeutics. Molecular Biology Reports, 53(1), Article 1620. https://doi.org/10.1007/s11033-026-12801-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12801-y

Keywords: leishmaniasis, multi-omics, CRISPR-Cas9, functional genomics, artificial intelligence, host-directed immunotherapy, drug resistance, trypanothione, sterol biosynthesis, neglected tropical diseases, drug discovery, precision medicine